SCHEMBL92943

SCHEMBL92943

CCc1cccc(COC2CCCCO2)c1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 1/20 0.41
CREBBP Q92793 2/20 0.40
EP300 Q09472 1/20 0.40
DHFR P00374 1/20 0.38
TACR1 P25103 4/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
ICAM1 P05362 1/20 0.37
SELE P16581 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
KDM1A O60341 1/20 0.35
AXL P30530 1/20 0.35
MERTK Q12866 1/20 0.35
KIF11 P52732 1/20 0.34
CARM1 Q86X55 1/20 0.34
PRMT6 Q96LA8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1732627 0.86 KDM4C (0.41) KDM4CCREBBPEP300DHFRTACR1
SCHEMBL7338156 0.86 KDM4C (0.41) KDM4CCREBBPEP300DHFRTACR1
SCHEMBL16318881 0.86 KDM4C (0.41) KDM4CCREBBPEP300DHFRTACR1
SCHEMBL12141797 0.85 ICAM1 (0.42) KDM4CCREBBPEP300TACR1SMN1; SMN2
SCHEMBL81144 0.84 KDM4C (0.46) KDM4CDHFRSMN1; SMN2NPC1RAB9A
SCHEMBL27353816 0.84 KDM4C (0.41) KDM4CCREBBPEP300DHFRTACR1
SCHEMBL8632096 0.83 ALDH1A1 (0.50) KDM4CDHFRTACR1NPC1RAB9A
SCHEMBL23662562 0.83 DHFR (0.43) KDM4CCREBBPEP300DHFRTACR1
SCHEMBL10214541 0.83 L3MBTL1 (0.47) KDM4CTACR1L3MBTL1CARM1PRMT6
SCHEMBL29865973 0.83 CA2 (0.45) KDM4CDHFRKDM1ACARM1PRMT6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129361-B2 Amine compound and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-03-06 US disclosed
US-20100179216-A1 AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179216-A1 AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF HLA-B, HLA-A, HLA-C KDM4C 1969/4885CREBBP 1673/4885EP300 1951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.